NASDAQ:DWTX Dogwood Therapeutics (DWTX) Stock Price, News & Analysis $5.64 -0.34 (-5.69%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$5.70 +0.06 (+1.06%) As of 03/28/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsBuy This Stock About Dogwood Therapeutics Stock (NASDAQ:DWTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dogwood Therapeutics alerts:Sign Up Key Stats Today's Range$5.52▼$6.2650-Day Range$1.87▼$17.4052-Week Range$1.62▼$29.28Volume102,647 shsAverage Volume1.92 million shsMarket Capitalization$7.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Read More… Remove Ads Receive DWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DWTX Stock News HeadlinesFY2024 Earnings Estimate for DWTX Issued By Zacks Small CapMarch 23, 2025 | americanbankingnews.comDogwood doses first patient in Phase 2b trial of HalneuronMarch 18, 2025 | markets.businessinsider.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. March 30, 2025 | Porter & Company (Ad)DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…March 18, 2025 | msn.comDogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic PainMarch 18, 2025 | globenewswire.comMaxim Group Remains a Buy on Dogwood Therapeutics (DWTX)March 13, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesMarch 13, 2025 | financialpost.comDogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving ForwardMarch 12, 2025 | financialpost.comSee More Headlines DWTX Stock Analysis - Frequently Asked Questions How have DWTX shares performed this year? Dogwood Therapeutics' stock was trading at $2.49 at the beginning of 2025. Since then, DWTX shares have increased by 126.5% and is now trading at $5.64. View the best growth stocks for 2025 here. How were Dogwood Therapeutics' earnings last quarter? Dogwood Therapeutics, Inc. (NASDAQ:DWTX) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.33) by $0.72. When did Dogwood Therapeutics' stock split? Dogwood Therapeutics shares reverse split on Wednesday, October 9th 2024. The 1-25 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Dogwood Therapeutics' major shareholders? Top institutional shareholders of Dogwood Therapeutics include Geode Capital Management LLC (0.82%) and Concourse Financial Group Securities Inc.. How do I buy shares of Dogwood Therapeutics? Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/07/2024Today3/30/2025Next Earnings (Estimated)4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DWTX CIK1818844 Webwww.dwtx.com Phone(866) 620-8655FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-217.12% Return on Assets-172.06% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book1.14Miscellaneous Outstanding Shares1,332,000Free Float1,169,000Market Cap$7.51 million OptionableN/A Beta2.07 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:DWTX) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredMan Who Predicted 2008 Crash: “Move your money out of stocks TODAY”Could the recent tech sell-off indicate a looming market crash? Nvidia dropped 30% from its high... Pala...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.